Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Bridgewater

Showing results (41-50 of 124) with videos related to

Pageof 13
Sort By:
Cancers|June 13, 2025
Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre StudyUmair Mahmood, Joanna Lynch, Simran Kaur Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialThierry André, Corrado Boni, Matilde Navarro, et al.
Journal of the National Cancer Institute|May 12, 2019
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical TrialsAngela Lamarca, Paul Ross, Harpreet S Wasan, et al.
Cancer Medicine|August 23, 2023
Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic functionPinkie Chambers, Matthew Watson, John Bridgewater, et al.
Oncotarget|December 8, 2017
Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trialSiân Pugh, Raphaële Thiébaut, John Bridgewater, et al.
The New England Journal of Medicine|April 9, 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerJuan Valle, Harpreet Wasan, Daniel H Palmer, et al.
The Lancet. Oncology|September 5, 2014
Guidance on the management of diarrhoea during cancer chemotherapyJervoise Andreyev, Paul Ross, Clare Donnellan, et al.
Hepatology (Baltimore, Md.)|July 28, 2023
Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trialsJulien Edeline, John Bridgewater, Boris Campillo-Gimenez, et al.
The New England Journal of Medicine|June 4, 2004
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancerThierry André, Corrado Boni, Lamia Mounedji-Boudiaf, et al.
Journal for Immunotherapy of Cancer|December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
Pageof 13

Showing results (41-50 of 124) with videos related to

Sort By:
Pageof 13
Cancers|June 13, 2025
Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre StudyUmair Mahmood, Joanna Lynch, Simran Kaur Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trialThierry André, Corrado Boni, Matilde Navarro, et al.
Journal of the National Cancer Institute|May 12, 2019
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical TrialsAngela Lamarca, Paul Ross, Harpreet S Wasan, et al.
Cancer Medicine|August 23, 2023
Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic functionPinkie Chambers, Matthew Watson, John Bridgewater, et al.
Oncotarget|December 8, 2017
Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trialSiân Pugh, Raphaële Thiébaut, John Bridgewater, et al.
The New England Journal of Medicine|April 9, 2010
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerJuan Valle, Harpreet Wasan, Daniel H Palmer, et al.
The Lancet. Oncology|September 5, 2014
Guidance on the management of diarrhoea during cancer chemotherapyJervoise Andreyev, Paul Ross, Clare Donnellan, et al.
Hepatology (Baltimore, Md.)|July 28, 2023
Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trialsJulien Edeline, John Bridgewater, Boris Campillo-Gimenez, et al.
The New England Journal of Medicine|June 4, 2004
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancerThierry André, Corrado Boni, Lamia Mounedji-Boudiaf, et al.
Journal for Immunotherapy of Cancer|December 17, 2025
Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint as a predictive biomarker for single-agent anti-PD-1Gary Middleton, Charlotte Gaskell, Joshua Savage, et al.
Pageof 13